Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age group 5-18 years with weight between ≥15 kg~* All subjects must have a confirmed diagnosis of malignancy~* European Cooperative Oncology Group (ECOG) performance status of 0,1 or 2~* Scheduled to receive highly emetogenic chemotherapy as assessed using the Pediatric Oncology Group of Ontario Guideline for emetogenicity Classification~* Patients receiving first cycle of chemotherapy~* Children's caregiver who can understand Hindi or English and are willing to participate in the study (with written informed consent)~Exclusion Criteria:~* Have had treatment within 14 days prior to study enrollment with olanzapine or 30 days prior to study enrollment with another antipsychotic agent~* Planned to receive quinolone antibiotics while receiving olanzapine~* Have uncontrolled hypertension~* Receive other antipsychotic agents, amifostine, citalopram, CYP1A2 inducers or inhibitors~* Have a history of neuroleptic malignant syndrome, a seizure disorder, hypersensitivity to olanzapine.~* Children with known cardiac disease~* Are pregnant or breast-feeding~* Had received or will receive RT to abdomen or pelvis in the week prior to treatment~* Vomited in the 24 hours prior to study~* Previous exposure to HEC~* Abnormal lab values (ANC\<1500/mm3, TLC\<3000/mm3, Plt\<100,000/mm3, AST/ALT\> 2.5 times of ULN, bill\>1.5 times of ULN, S.cr\>1.5 times of ULN, patient on systemic steroids

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Patient on control group (ODA) with weight category of 15-40 kg will receive:~D1-D3 Dexamethasone 3 mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg;~The patient on control group with weight category of \> 40 kg will receive:~D1- Dexamethasone 3 mg/m2 , ondansetron(0.15 mg/kg ), Aprepitant 125 mg; D2-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg~Note: Aprepitant will be administered as single oral dose, dexamethasone and ondansetron will be administered q 8h (PO/IV)
- Arm B (Type: EXPERIMENTAL): weight category of 15-40 kg will receive: D1-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg and olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D4-olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg)~Weight category of \> 40 kg in study group will receive:~D1- Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg, ), Aprepitant 125 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D2-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D4-olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) Note: Aprepitant \& Olanzapine will be administered as single oral dose, dexamethasone and ondansetron will be administered q 8h (PO/IV)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete